LY900003: Clinical Trials

1 trial of LY900003, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Completed 1

Follow LY900003: new trials by email Literature Review of LY900003 trials Research Report on LY900003

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
Gemcitabine, Carboplatin, LY900003 - Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms
Phase 2CompletedEli Lilly and Company2002-06-012006-07-19

Conditions studied

Adenocarcinoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Squamous Cell (1)  ·  Lung Neoplasms (1)

Sponsors

Eli Lilly and Company (1)

Countries

United States (1)